Beam Therapeutics Presents Data Highlighting Robust Manufacturing Process For BEAM-101 At EHA 2024 Hybrid Congress June 13-16, 2024

5/14/24 4:00:52 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BEAM alert in real time by email

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on June 13-16, 2024.

Abstract details are listed below and available online on the EHA meeting library website.

Title: Robust autologous CD34+ HSPC manufacturing with a closed and automated process optimized for patients with sickle cell disease

Poster Session Date and Time: Friday, June 14, 2024, 6:00 p.m. CEST

Abstract: P1479

Presenting Author: Paul Kopesky, Ph.D., vice president, process development at Beam Therapeutics

Get the next $BEAM alert in real time by email

Date	Price Target	Rating	Analyst
11/6/2024	$27.00 → $39.00	Market Perform → Outperform	Leerink Partners
10/16/2024		Sector Outperform	Scotiabank
7/23/2024	$80.00	Buy	H.C. Wainwright
1/29/2024	$38.00 → $40.00	Neutral → Overweight	JP Morgan
12/15/2023	$35.00	Buy → Neutral	BofA Securities
12/8/2023	$75.00 → $30.00	Buy → Hold	Jefferies
10/20/2023		Overweight → Neutral	Cantor Fitzgerald
10/20/2023	$75.00 → $20.00	Outperform → Market Perform	Leerink Partners

Beam Therapeutics Presents Data Highlighting Robust Manufacturing Process For BEAM-101 At EHA 2024 Hybrid Congress June 13-16, 2024

Chat with this insight

Recent Analyst Ratings for $BEAM

$BEAM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President Ciaramella Giuseppe sold $1,347,050 worth of shares (51,110 units at $26.36), decreasing direct ownership by 32% to 109,150 units (SEC Form 4)

President Ciaramella Giuseppe exercised 41,754 shares at a strike of $2.00 and sold $1,342,752 worth of shares (51,110 units at $26.27), decreasing direct ownership by 6% to 160,260 units (SEC Form 4)

Chief Legal Officer Bellon Christine sold $9,040 worth of shares (385 units at $23.48), decreasing direct ownership by 0.37% to 104,209 units (SEC Form 4)

$BEAM Financials

Live finance-specific insights

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

$BEAM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Beam Therapeutics upgraded by Leerink Partners with a new price target

Scotiabank initiated coverage on Beam Therapeutics

H.C. Wainwright initiated coverage on Beam Therapeutics with a new price target

$BEAM SEC Filings

SEC Form 10-Q filed by Beam Therapeutics Inc.

Beam Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Beam Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$BEAM Market Insights

Live Market Insights

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

Beam Therapeutics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced an $80 price target.

HC Wainwright & Co. Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $80

$BEAM Press Releases

Fastest customizable press release news feed in the world

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

$BEAM Leadership Updates

Live Leadership Updates

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

$BEAM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

Recent Analyst Ratings for
$BEAM

$BEAM
Insider Trading

$BEAM
Financials

$BEAM
Analyst Ratings

$BEAM
SEC Filings

$BEAM
Market Insights

$BEAM
Press Releases

$BEAM
Leadership Updates

$BEAM
Large Ownership Changes